Thoughts on Intarcia’s Second CRL

The news of Intarcia receiving a second CRL for ITCA-650 (previous FENIX insight) brings about several thoughts and potential market implications. Below, FENIX provides its latest thinking in a favors/disfavors analysis about Intarcia, the GLP-1RA market, and a reminder that others in diabetes have received FDA approval after 2 CRLs.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.